candiforce-100 100 mg oral solid ordinary capsules
mankind pharma limited - itraconazole - oral solid ordinary capsules - 100 mg
bactafuz 2% w/w topical external creams
mankind pharma limited - fusidic acid - topical external creams - 2% w/w
bactafuz-b 2% w/w + 0.1%w/w topical external creams
mankind pharma limited - fusidic acid + betamethasone valerate - topical external creams - 2% w/w + 0.1%w/w
brutaflam-120 120mg oral solid ordinary film-coated tablets
mankind pharma limited - etoricoxib - oral solid ordinary film-coated tablets - 120mg
feblorika-80 80 mg oral solid ordinary film-coated tablets
mankind pharma limited - febuxostat - oral solid ordinary film-coated tablets - 80 mg
feblorika-40 40mg oral solid ordinary film-coated tablets
mankind pharma limited - febuxostat - oral solid ordinary film-coated tablets - 40mg
uniortho-500 oral solid ordinary film-coated tablets
mankind pharma ltd.; tata uganda limited - oral solid ordinary film-coated tablets
candiforce-100 100 mg capsule
mankind pharma ltd.; importer: i.e. medica, inc.; distributor: i.e. medica, inc. - itraconazole - capsule - 100 mg
none 100 mg capsule
mankind pharma ltd.; importer: i.e. medica, inc.; distributor: i.e. medica, inc. - itraconazole - capsule - 100 mg
nitrofurantoin macrocrystals capsule
bluepoint laboratories - nitrofurantoin (unii: 927ah8112l) (nitrofurantoin - unii:927ah8112l) - nitrofurantoin capsules (macrocrystals) are specifically indicated for the treatment of urinary tract infections when due to susceptible strains of escherichia coli , enterococci, staphylococcus aureus , and certain susceptible strains of klebsiella and enterobacter species. nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. to reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin capsules (macrocrystals) and other antibacterial drugs, nitrofurantoin capsules (macrocrystals) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. nitrofurantoins lack the broader tissue distributio